OTCMKTS:GNGBY

Getinge AB (publ) - GNGBY Stock Forecast, Price & News

$23.36

+0.40 (+1.74%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $23.18
▼
$23.36
50-Day Range: $20.26
▼
$24.84
52-Week Range: $15.87
▼
$41.54

Volume: 2,870 shs
Average Volume: 7,784 shs
Market Capitalization: $6.36 billion

P/E Ratio: 25.96
Dividend Yield: 1.28%
Price Target: N/A

About Getinge AB (publ) (OTCMKTS:GNGBY) Stock

Getinge AB is a medical technology company specializes in providing equipment, systems, operating rooms, intensive-care units to the healthcare and the life science industries. It offers products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. The firm operates through the following segments: Acute Care Therapies, Life Science and Surgical Workflows. The Acute Care Therapies segment offers solutions for life support in acute health conditions. The Life Science segment offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in biopharmaceutical production, biomedical research, medical device manufacturing and laboratory applications. The Surgical Workflows segment offers products and services for efficient disinfection and sterilization of instruments used in operations, operating tables and other high-quality hardware for operating rooms and advanced IT systems for efficient and secure hospital workflows. The company was founded by Olander Larsson in 1904 and is headquartered in Gothenburg, Sweden.

Receive GNGBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Getinge AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

GNGBY Stock News Headlines

March 24, 2023 | finance.yahoo.com

Getinge recieves FDA premarket approval for the iCast™ covered stent system in the US

March 17, 2023 | finance.yahoo.com

US FDA classifies recall of heart devices by Getinge as most serious

March 26, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

January 27, 2023 | reuters.com

FDA classifies recall of Getinge's heart devices as most serious

January 25, 2023 | finance.yahoo.com

UPDATE 1-FDA classifies recall of Getinge's heart devices as most serious

December 19, 2022 | finance.yahoo.com

INSIGHT-Medical device makers drop products as EU law sows chaos

September 22, 2022 | seekingalpha.com

GNGBY Getinge AB (publ)

July 19, 2022 | seekingalpha.com

Getinge AB (GNGBF) CEO Mattias Perjos on Q2 2022 Results - Earnings Call Transcript

March 26, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

April 26, 2022 | seekingalpha.com

Getinge AB (publ) Non-GAAP EPS of SEK 2.11, revenue of SEK 6.18B

April 26, 2022 | finance.yahoo.com

Getinge Interim Report January-March 2022: Healthy order book but supply chain challenges

January 28, 2022 | finance.yahoo.com

Getinge Year End Report 2021: "Healthy order growth, improved EBITA margin and strong cash flow"

January 27, 2022 | tmcnet.com

Getinge Launches State-of-the-Art Experience Center in New Jersey to Showcase Innovations in Healthcare and Medical Technology

January 19, 2022 | uk.finance.yahoo.com

Getinge appoints Elin Frostehav as President Acute Care Therapies and Eric Honroth as President Life Science

October 22, 2021 | seekingalpha.com

Getinge AB's (GNGBF) CEO Mattias Perjos on Q3 2021 Results - Earnings Call Transcript

October 20, 2021 | finance.yahoo.com

Getinge Q3 Report 2021: "Strong order intake and our remediation measures completed in Germany"

October 20, 2021 | seekingalpha.com

Getinge AB 2021 Q3 - Results - Earnings Call Presentation

August 21, 2021 | barrons.com

Getinge AB ADR

August 20, 2021 | finance.yahoo.com

Here's What Could Help GETINGE AB (GNGBY) Maintain Its Recent Price Strength

August 3, 2021 | finance.yahoo.com

Getinge Joins AdvaMed, Reinforcing Global Commitment to Advancing Innovation in Medical Technology and Improving Healthcare Policy and Patient Outcomes

July 27, 2021 | finance.yahoo.com

GETINGE AB (GNGBY) is on the Move, Here's Why the Trend Could be Sustainable

July 16, 2021 | seekingalpha.com

Getinge AB reports Q2 results

July 16, 2021 | seekingalpha.com

Getinge AB 2021 Q2 - Results - Earnings Call Presentation

June 4, 2021 | finance.yahoo.com

Getinge grows with social funding

May 6, 2021 | stocknews.com

4 of the Best Stocks to Add to Your Portfolio Right Now

April 22, 2021 | finance.yahoo.com

Getinge receives US FDA 510(k) clearance for three products, expanding the Servo ventilator platform

April 18, 2021 | markets.businessinsider.com

Getinge AB is about to announce its earnings — here's what Wall Street expects

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GNGBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Getinge AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

GNGBY Company Calendar

Last Earnings: 2/01/2023
Today: 3/25/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Electromedical equipment
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:GNGBY
CUSIP: N/A
CIK: N/A
Web: www.getinge.com
Phone: (610) 335-0000
Fax: 46-1-033-556-40
Employees: 10,700
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $0.90
Trailing P/E Ratio: 25.96
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $246.86 million
Net Margins: 8.83%
Pretax Margin: 12.27%
Return on Equity: 10.07%
Return on Assets: 5.91%

Debt

Debt-to-Equity Ratio: 0.15
Current Ratio: 1.44
Quick Ratio: 0.97

Sales & Book Value

Annual Sales: $2.81 billion
Price / Sales: 2.27
Cash Flow: $1.88 per share
Price / Cash Flow: 12.40
Book Value: $11.08 per share
Price / Book: 2.11

Miscellaneous

Outstanding Shares: 272,370,000
Free Float: N/A
Market Cap: $6.36 billion
Optionable: Not Optionable
Beta: 1.26

Key Executives

Mattias Sven Perjos
President, Chief Executive Officer & Director

Lars Sandström
Chief Financial Officer

Anna Romberg
Executive VP-Legal, Compliance & Governance

Carsten Blecker
Chief Commercial Officer

Jens Viebke
President-Acute Care Therapies Business

Key Competitors

View All Competitors

GNGBY Stock - Frequently Asked Questions

Should I buy or sell Getinge AB (publ) stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Getinge AB (publ) in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GNGBY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GNGBY, but not buy additional shares or sell existing shares.
View GNGBY analyst ratings or view top-rated stocks.
How have GNGBY shares performed in 2023?: Getinge AB (publ)'s stock was trading at $20.62 at the beginning of the year. Since then, GNGBY stock has increased by 13.3% and is now trading at $23.36.
View the best growth stocks for 2023 here.
Are investors shorting Getinge AB (publ)?: Getinge AB (publ) saw a decline in short interest in February. As of February 28th, there was short interest totaling 2,900 shares, a decline of 39.6% from the February 13th total of 4,800 shares. Based on an average daily trading volume, of 12,200 shares, the days-to-cover ratio is presently 0.2 days.
View Getinge AB (publ)'s Short Interest.
How were Getinge AB (publ)'s earnings last quarter?: Getinge AB (publ) (OTCMKTS:GNGBY) announced its quarterly earnings results on Wednesday, February, 1st. The company reported $0.31 EPS for the quarter. The firm had revenue of $793.05 million for the quarter. Getinge AB (publ) had a net margin of 8.83% and a trailing twelve-month return on equity of 10.07%.
How often does Getinge AB (publ) pay dividends? What is the dividend yield for Getinge AB (publ)?: Getinge AB (publ) announced a dividend on Wednesday, April 20th. Stockholders of record on Thursday, April 28th will be given a dividend of $0.3116 per share on Wednesday, May 18th. This represents a yield of 0.85%. The ex-dividend date is Wednesday, April 27th.
Read our dividend analysis for GNGBY.
Is Getinge AB (publ) a good dividend stock?: Getinge AB (publ) (OTCMKTS:GNGBY) pays an annual dividend of $0.30 per share and currently has a dividend yield of 1.30%. The dividend payout ratio is 33.33%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for GNGBY.

What is Getinge AB (publ)'s stock symbol?: Getinge AB (publ) trades on the OTCMKTS under the ticker symbol "GNGBY."
How do I buy shares of Getinge AB (publ)?: Shares of GNGBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Getinge AB (publ)'s stock price today?: One share of GNGBY stock can currently be purchased for approximately $23.36.
How much money does Getinge AB (publ) make?: Getinge AB (publ) (OTCMKTS:GNGBY) has a market capitalization of $6.36 billion and generates $2.81 billion in revenue each year. The company earns $246.86 million in net income (profit) each year or $0.90 on an earnings per share basis.
How many employees does Getinge AB (publ) have?: The company employs 10,700 workers across the globe.
How can I contact Getinge AB (publ)?: Getinge AB (publ)'s mailing address is LINDHOLMSPIREN 7A, GOTHENBURG V7, 41756. The official website for the company is www.getinge.com. The company can be reached via phone at (610) 335-0000, via email at lars.mattsson@getinge.com, or via fax at 46-1-033-556-40.

This page (OTCMKTS:GNGBY) was last updated on 3/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial